MajorAntiretroviral, HIV protease inhibitor×Antifungal, triazole
Updated · Methodology
Mechanism
Itraconazole, like ketoconazole, is a strong inhibitor and a substrate of CYP3A4 (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5; itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.5 and 5.2). With other boosted protease inhibitors, the ketoconazole area under the concentration–time curve (AUC) rose threefold. Atazanavir with ritonavir is therefore expected to raise ketoconazole and itraconazole levels (atazanavir SmPC, EMA, section 4.5). With unboosted atazanavir 400 mg, ketoconazole 200 mg had no significant effect on atazanavir levels (atazanavir SmPC, EMA, section 4.5). With atazanavir plus cobicistat, itraconazole and cobicistat levels may rise, and itraconazole, as a CYP3A inhibitor, may also raise atazanavir levels (atazanavir/cobicistat SmPC, EMA, section 4.5). The itraconazole SmPC considers it likely that ritonavir and cobicistat raise itraconazole levels and that itraconazole raises theirs (itraconazole SmPC, AEMPS, section 4.5).
Symptoms
The documents describe no symptoms specific to this combination. The risk is linked to higher itraconazole levels and stronger itraconazole adverse reactions (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5; itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The most common adverse reactions of itraconazole are headache, abdominal pain and nausea. The most serious are severe allergic reactions, heart failure, pulmonary oedema, pancreatitis, severe liver toxicity and severe skin reactions. Heart failure was reported more often with a total daily dose of 400 mg than with lower doses (itraconazole SmPC, AEMPS, sections 4.4 and 4.8). Common effects of atazanavir are nausea, diarrhoea and jaundice due to a reversible rise in unconjugated bilirubin (atazanavir SmPC, EMA, sections 4.4 and 4.8).
Management
With atazanavir plus ritonavir, itraconazole is used with caution, and high itraconazole doses (more than 200 mg a day) are not recommended (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5). For atazanavir plus cobicistat, there are no specific dose recommendations, and caution is advised. If the combination is needed, the daily itraconazole dose should not exceed 200 mg (atazanavir/cobicistat SmPC, EMA, section 4.5). The US atazanavir label says high itraconazole doses (more than 200 mg a day) should be used cautiously with atazanavir plus ritonavir (Reyataz prescribing information, US Food and Drug Administration, FDA, section 7). The Spanish itraconazole SmPC lists ritonavir and cobicistat among drugs to be used with caution. It calls for close monitoring for signs of increased or prolonged effects and adverse reactions (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The US itraconazole label adds that the itraconazole dose may need to be reduced (Sporanox prescribing information, FDA, section 7). If signs of congestive heart failure appear, itraconazole is stopped (itraconazole SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Sporanox (itraconazole) capsules prescribing information (2026)– Janssen Pharmaceuticals. SPORANOX (itraconazole) capsules. Prescribing information, DailyMed setid a4d555fa-787c-40fb-bb7d-b0d4f7318fd0, Contraindications and Drug Interactions table
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- AEMPS: Ficha técnica: Itraconazol (nº registro 59343), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59343 (Sporanox 100 mg cápsulas), revisión 07/2025, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5